+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026

  • ID: 5239819
  • Report
  • February 2021
  • Region: Global
  • 330 Pages
  • Kuick Research
UP TO OFF
until Apr 30th 2021
1 of 4

FEATURED COMPANIES

  • Angimmune
  • Astrazeneca
  • Eisai
  • Molecular Template (mTEM)
  • Neopharma
  • Roche
  • MORE

Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026 Report Highlights:

  • Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
  • Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million 
  • Biological Toxins Drug Insight by Cancer 
  • Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
  • Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

The fast pace of cancer prevalence and mortality rate across the globe has led to an increasing concern as well as recognition that the specific disease requires attention by the researchers. In the past few years, the type of research activities that have been conducted for cancer disease has moved several laboratory findings to the commercial world. In one of the scenarios, development of cancer biological toxins is a form of novel technology facility resulted from the translational research conducted at different research centers. The therapy developed and re-defined by hundreds of researchers in the past few years is witnessed to facilitate promising cancer targets in its preclinical as well as clinical research. The comprehensive outlook for the market appears to the positive, in terms of sustainable results achieved and its wide range applications to alter the future cancer therapeutics landscape. 

While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable. The market since its emergence has remained ahead with respect to the overall survival rate it is delivering as well as solving the entire healthcare problems related with cancer development and progression. Several drug makers in today’s world are getting involved in boosting the value chain of the market by delivering conventional thinking and re-defining the entire role of their research and development sector for the market expansion. 

The market since its arrival in the cancer therapeutics market at global level has remained successful in reconfiguring today’s cancer challenges by causing a shift from only being a therapy to becoming one of the standard healthcare regimens for millions of patients. All this is inclining the market towards poised growth, where in the next few years, the market will observe an influx in the market size by huge percentage. The several highlights of the market are also projecting increase in demand of the drug products available under it as the disease lifestyle is becoming more prevalent, thus making the researchers unlock more hidden potential of the therapy for different cancer patient types. 

Traditionally, the cancer biological toxin market is prone to deliver and provide value in terms of complete eradication of the cancer cells by performing splendid research and development activities. But an important reason that has led to substantial rise in the clinical and research activities related with cancer is the overhaul that the other available cancer therapies had created for the past many decades. This resulted in the foundational shift in the entire cancer therapeutics industry and thus, the emergence of therapy that involves toxins isolated from prokaryotes for killing the cancer cells. To date, researchers have been successful in isolating and studying the expression of biological toxins from different organisms for killing cancer cells but one most studied bacterium for the therapy is Clostridium botulinum. 

The respective bacterium and several others have promised highest returns for the cancer patients. Also, the toxins isolated from such living organisms and their transformation into drug products have led to the representation of the therapy in top best-selling cancer therapies at global level. The market due to several ongoing processes and certain achievements of the past is expected to continue to observe strong growth, with a CAGR rate of double-digit. There are numerous parameters that are associated with the market and acting as drivers. Some of the driving forces for the market are: increase in cancer cases, increase in cancer mortality rate, increase in awareness about the applications of cancer biological toxins and high failure rate of other therapies available in the market. 

The unexpected status of the cancer biological toxin market has also resulted in challenging the business model of other therapies. The market’s growing research spending amount and involvement of leading players of the pharmaceutical industry are also causing a robust demonstration of the applications and wide healthcare opportunities associated with the market. In addition, the therapy market is being measured as a superior therapy carrying all parameters for getting classified as a standard of care rather than just a usual cancer therapy for the patients. The healthy outcomes associated with the market are also directly linking the market to hedge over the highly expensive market such as chemotherapy, immunotherapy or any other combination therapy. 

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Angimmune
  • Astrazeneca
  • Eisai
  • Molecular Template (mTEM)
  • Neopharma
  • Roche
  • MORE

1. Introduction to Biological Toxins
1.1 Overview
1.2 Evolution of Biological Toxins as Potent Anticancer Therapeutics

2. Role of Biological Toxins in Cancer Management

3. Types of Biological Toxins for Targeting Cancer
3.1 Single Chain Biological Toxins
3.2 Pore Forming Toxins
3.3 Anthrax Toxins

4. Impact of Growing Cancer Biological Toxin Market on Other Viable Cancer Therapies
4.1 Global Impact of Cancer Biological Toxin Therapy Market on Cancer Immunotherapy Market
4.1.1 Cancer Biological Toxin Therapy Vs. Immune Checkpoint Inhibitor Therapy
4.1.2 Cancer Biological Toxin Therapy Vs. Immunotherapy Monoclonal Antibodies
4.1.3 Cancer Biological Toxins Therapy Market Vs. Cancer Vaccine Market
4.2 Global Impact of Cancer Biological Toxin Therapy Market on Old & Traditional Cancer Therapies
4.2.1 Cancer Biological Toxin Therapy Market Vs. Chemotherapy for Cancer Patients
4.2.2 Cancer Biological Toxin Therapy Market Vs. Radiation Therapy for Cancer Treatment
4.2.3 Cancer Biological Toxin Therapy Vs. Surgical Procedure for Cancer Treatment

5. Biological Toxins for Brain Tumors
5.1 Toxins Used for Targeting Brain Tumors
5.2 Pseudomonas Exotoxin-Based Immunotoxins for Brain Tumors
5.2.1 IL4-PE
5.2.2 IL13-PE
5.2.3 TP-38
5.3 Diphtheria Toxin-Based Immunotoxins for Brain Tumor
5.3.1 Tf-CRM107
5.3.2 DTAT & DTAT13
5.4 Antigens for Targeting Brain Tumor
5.4.1 Transferrin Receptor
5.4.2 Interleukin-4 Receptor
5.4.3 Interleukin-13 Receptor
5.4.4 Epidermal Growth Factor Receptor
5.4.5 Other Antigens

6. Biological Toxins Against Hematological Tumors
6.1 Role of Biological Toxins in Leukemia & Lymphoma
6.2 Ongoing Research & Development

7. Biological Toxins For Targeting Solid Tumors
7.1 Impact on Solid Tumor Treatment
7.2 Ongoing Research & Advancements

8. Biological Toxins for Breast Cancer
8.1 Application of Biological Toxins in Breast Cancer
8.2 Ongoing Development

9. Biological Toxins for Lung Cancer
9.1 Role & Applications
9.2 Recent Research & Development

10. Biological Toxins For Other Cancers
10.1 Prostate Cancer
10.2 Melanoma
10.3 Colorectal Cancer
10.4 Gynecological Cancer
10.5 Gastrointestinal Cancers

11. Global Immunotoxin Market – Availability, Dosage, Patent & Price Analysis
11.1 Lumoxiti (Moxetumomab pasudotox)

12. Research & Medical Advancement for Cancer Biological Toxin Market
12.1 UCLA Researchers to Minimize Cancer Side Effects by Using Protein Derived from Diazona angulata
12.2 Botulinum Toxin Effective against Stomach Cancer Cells in the Patients
12.3 Botulinum Toxin A to Drastically Reduce Complications After Esophageal Cancer Treatment
12.4 Botulinum Toxin A against Cutaneous Leiomyomas Indicating for Better Results
12.5 TR1801-ADC Characterization for the Treatment of Advanced Solid Cancer
12.6 Botulinum Toxin to Increase the Effectiveness of Chemotherapy & Radiation Therapy
12.7 Botulinum Toxin A Cure for Persistent Pain after Breast Cancer Surgery
12.8 Newly Discovered Botulinum Toxin X to have Potential for Treating Cancer & Other Diseases

13. Cancer Biological Toxins – Clinical Trial Insight
13.1 By Phase
13.2 By Status
13.3 By Cancer Type
13.4 By Countries

14. Global Cancer Biological Toxins Clinical Pipeline By Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-II/III
14.7 Phase-III
14.8 Preregistration
14.9 Registered

15. Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

16. Global Cancer Biological Toxin Therapeutics Market Dynamics
16.1 Favourable Market Parameters
16.2 Market Challenges

17. Future Directions for Cancer Biological Toxin Market

18. Competitive Landscape
18.1 Angimmune
18.2 Eisai
18.3 Molecular Template (mTEM)
18.4 Astrazeneca
18.5 Research Corporation Technologies
18.6 Sanofi
18.7 Seattle Genetics
18.8 Roche
18.9 Neopharma
18.10 Xenova Biomedix

List of Figures
Figure 1-1: Evolution of Biological Toxins as Anticancer Therapeutics
Figure 2-1: Management of Biological Toxins in Cancer Treatment
Figure 3-1: Components of Immunotoxins
Figure 3-2: Components of Targeted Toxins
Figure 3-3: Types of Cancer Targeting Biological Toxins
Figure 3-4: Structure of Diphtheria Toxin & Denileukin diftitox (Ontak)
Figure 3-5: Mechanism of Denileukin diftitox (Ontak)
Figure 3-6: Mechanism of Pore Forming Biological Toxins
Figure 4-1: Cancer Biological Toxins Vs. Monoclonal Antibody
Figure 4-2: Old & Traditional Cancer Therapies Available in Therapeutics Market
Figure 4-3: Cancer Biological Toxin Therapy Action Vs. Chemotherapy Drug Action
Figure 4-4: Cancer Biological Toxin Vs. Surgical Removal of Cancer Cells
Figure 5-1: Commonly used Biological Toxins for Targeting Brain Tumor
Figure 5-2: Pseudomonas Exotoxin Based Immunotoxins
Figure 5-3: Diphtheria Toxin Based Immunotoxins under Development Phase
Figure 5-4: Antigens/ Receptors for Targeting Brain Tumor
Figure 5-5: Cintredekin Besudotox - Orphan Drug Designation Year by Indication
Figure 5-6: D2C7-IT Trial - Trial Initiation & Expected Completion Year
Figure 5-7: Role of Urokinase-Type Plasminogen Activator Receptor in Brain Tumor
Figure 6-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 6-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 6-3: Commonly used Biological Toxins for Targeting Haematological Tumor
Figure 6-4: Target Receptor for Ontak
Figure 6-5: Resimmune - FDA Orphan Designation & Fast Track Designation Year
Figure 6-6: Immunotoxin Receptors for Haematological Cancer
Figure 6-7: Investigational Immunotoxins for Haematological Cancer
Figure 6-8: Mechanism of LMB2 against Cells of Hematological Tumors
Figure 6-9: LMB-2 Phase II Trial - Study Initiation & Expected Completion Year
Figure 6-10: LMB-2 Phase I/II Trial - Study Initiation & Expected Completion Year
Figure 6-11: BL22 (CAT-3888) - Mechanism of Action against Hematological Malignancy
Figure 6-12: DT388GMCSF: Mechanism of Action Against Leukemia Cells
Figure 6-13: Resimmune - Mechanism of Action Against Cutaneous T Cell Lymphoma
Figure 6-14: Mechanism of MT-3724 in Hematological Cancer
Figure 6-15: MT-3724 Phase I/II Trial - Study Initiation & Expected Completion Year
Figure 6-16: MT-3724 Phase II Trial - Study Initiation & Expected Completion Year
Figure 7-1: Biological Toxins for Targeting Solid Tumors
Figure 7-2: Limitations of Immunotoxins in Solid Tumors
Figure 7-3: Immunotoxin for Solid Tumors by Target Receptor
Figure 7-4: Investigational Immunotoxins for Solid Tumor
Figure 7-5: SS1P - Mechanism of Action against Solid Tumor
Figure 7-6: LMB-100 - Mechanism of Action against Solid Tumors
Figure 7-7: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
Figure 7-8: LMB-100 Phase I/II Trial - Study Initiation & Expected Completion Year
Figure 7-9: LMB-7 - Mechanism of Action against Solid Tumors
Figure 8-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
Figure 8-2: Biological Toxins Used for Targeting Breast Cancer
Figure 8-3: Approaches Used to Overcome Immunogenicity
Figure 8-4: Investigational Immunotoxins for Breast Cancer
Figure 9-1: Global - Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
Figure 9-2: Biological Toxins used for Targeting Lung Cancer
Figure 9-3: Antigens/Receptors Expressed Over Lung Cancer Cells
Figure 9-4: Investigational Immunotoxins for Lung Cancer
Figure 10-1: Global - Newly Diagnosed Cases & Deaths related to Prostate Cancer (Million), 2020
Figure 10-2: Commonly used Biological Toxins for Targeting Prostate Cancer
Figure 10-3: Role of A-dmDT390-ScfbDb(PSMA) in Prostate Cancer
Figure 10-4: Investigational Immunotoxins for Prostate Cancer
Figure 10-5: Global - Newly Diagnosed Cases & Deaths related to Melanoma, 2020
Figure 10-6: Mechanism of PE Based Immunotoxins against Melanoma Cells
Figure 10-7: Antigens/Receptors Expressed Over Melanoma Cells
Figure 10-8: Mechanism of 9.2.27PE
Figure 10-9: Global - Newly Diagnosed Cases & Deaths related to Colon Cancer (Million), 2020
Figure 10-10: Global - Newly Diagnosed Cases & Deaths related to Rectum Cancer (Million), 2020
Figure 10-11: Antigens/Receptors Expressed Over Cells of Colorectal Cancer
Figure 10-12: Investigational Immunotoxins for Colorectal Cancer
Figure 10-13: BM7PE Trial - Study Initiation & Expected Completion Year
Figure 10-14: Global - Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
Figure 10-15: Global - Number of Deaths by Leading Gynecological Cancer, 2020
Figure 10-16: Antigens/Receptors Expressed Over Cells of Gynecological Cancers
Figure 10-17: Investigational Immunotoxins for Gynecological Cancer
Figure 10-18: Global - Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
Figure 10-19: Global - Number of Deaths by Leading Gastrointestinal Cancer, 2020
Figure 10-20: Antigens/Receptors Expressed Over Cells of Gastrointestinal Cancers
Figure 10-21: Investigational Immunotoxins for Gastrointestinal Cancer
Figure 10-22: LMB-100 Phase Ib/II Trial - Study Initiation & Expected Completion Year
Figure 10-23: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
Figure 11-1: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 11-2: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks), January’2021
Figure 11-3: Lumoxiti - Number of Dose Required in Single Treatment Cycle & Full Treatment, January’2021
Figure 11-4: Lumoxiti - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January’2021
Figure 13-1: Global - Number of Cancer Biological Toxins Related Clinical Trials by Phase, January’2021
Figure 13-2: Global - Cancer Biological Toxins Related Clinical Trials by Phase (%), January’2021
Figure 13-3: Global - Number of Cancer Biological Toxins Related Clinical Trials by Status, January’2021
Figure 13-4: Global - Cancer Biological Toxins Related Clinical Trials by Status (%), January’2021
Figure 13-5: Global - Number of Cancer Biological Toxins Related Clinical Trials by Indication, January’2021
Figure 13-6: Global - Cancer Biological Toxins Related Clinical Trials by Indication (%), January’2021
Figure 13-7: Global - Number of Cancer Biological Toxins Related Clinical Trials by Region, January’2021
Figure 13-8: Global - Number of Cancer Biological Toxins Related Phase I Clinical Trials by Region, January’2021
Figure 13-9: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January’2021
Figure 13-10: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January’2021
Figure 16-1: Drivers for the Growth of Cancer Biological Toxin Market
Figure 17-1: Global - Cancer Biological Toxins Expected Market Opportunity (US$ Million), 2021 -2026
Figure 17-2: Parameters Driving the Future Insight for Cancer Biological Toxin Market

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Angimmune
  • Eisai
  • Molecular Template (mTEM)
  • Astrazeneca
  • Research Corporation Technologies
  • Sanofi
  • Seattle Genetics
  • Roche
  • Neopharma
  • Xenova Biomedix
Note: Product cover images may vary from those shown
Adroll
adroll